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3Extent of Nonadherence Across the Population
At any 
given time
~50% of 
patients are 
non-adherent
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:
National Association of Chain Drug Stores Pharmacies: Improving Health, Reducing Costs. July 2010. Based on IMS Health data. 
Image courtesy of Zullig L. 
Christensen A, Osterberg LG, Hansen EH. J Hypertens. 2009 Aug;27(8):1540–51.
4Adherence Is The Process by Which Patients Take Their 
Medications as Prescribed
Vrijens B, De Geest S, Hughes DA, et al. Br J Clin Pharmacol. 2012 May;73(5):691-705.
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5Lower Adherence Associated with Greater Risk 
of Major Adverse Cardiac Event
Adherence is Linked to Clinical Outcomes
Vlasnik JJ, Aliotta SL, DeLor B. Case Manager. 2005 Mar-Apr;16(2):47-51.
Simpson SH, Eurich DT, Majumdar SR, et al. BMJ. 2006 Jul 1;333(7557):15.
Figure: Bansilal S, Castellano JM, Garrido E, et al. J Am Coll Cardiol. 2016 Aug 23;68(8):789-801
Medication nonadherence 
in the U.S. costs 
$100 billion‒$300 billion 
per year
33%‒69% of hospital 
admissions are due 
to nonadherence
Good adherence 
reduces adverse events 
and mortality PDC = Proportion of days covered (adherence measured with pharmacy refill data)
6Nonadherence Is Multifactorial
Ferdinand KC, Senatore FF, Clayton-Jeter H, et al. Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications. J 
Am Coll Cardiol. 2017 Jan 31;69(4):437-451.
Socioeconomic factors
● Lower social economic status associated with lower adherence
Health care system factors
● Team-based care and post-hospital follow-up improve adherence
Medical condition-related disease factors
● Concomitant conditions and comorbidities can impact adherence
7More Factors that Impact Adherence
Therapy-related factors
● Side effects of medications
● Number and different types of pills to be taken
● Complexity or changes to regimen
Patient-related factors
● Understanding of disease, its course and 
possible complications 
● Expectations of improvement on medication
● Perceptions of symptoms, either improving 
or worsening 
Ferdinand KC, Senatore FF, Clayton-Jeter H, et al. Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications. J 
Am Coll Cardiol. 2017 Jan 31;69(4):437-451.
8Medication Adherence Interventions Can Impact Nonadherence
Conn VS, Ruppar TM, Chase JA, et al. Curr Hypertens Rep. 2015 Dec;17(12):94.
Chase JA, Bogener JL, Ruppar TM,et al. J Cardiovasc Nurs. 2016 Jul-Aug;31(4):357-66. 
Ruppar TM, Delgado JM, Temple J. Eur J Cardiovasc Nurs. 2015 Oct;14(5):395-404.
Condition
Number 
of 
Studies
Total Number 
of Patients
Effect size 95% C.I. P-value
Hypertension 112 34,272 0.42 0.32, 0.52 <.001
Coronary artery disease 28 18,839 0.23 0.14, 0.32 <.001
Heart failure 29 4,285 0.29 0.09, 0.48 .004
Meta-Analyses of Medication Adherence Intervention Outcomes
9Understanding Interventions Impact on Nonadherence
Conn VS, Ruppar TM, Chase JA, et al. Curr Hypertens Rep. 2015 Dec;17(12):94.
Chase JA, Bogener JL, Ruppar TM,et al. J Cardiovasc Nurs. 2016 Jul-Aug;31(4):357-66. 
Ruppar TM, Delgado JM, Temple J. Eur J Cardiovasc Nurs. 2015 Oct;14(5):395-404.
Evaluating the effect of an 
intervention on adherence
● Medication adherence needs to be 
measured in valid, reliable and cost-
effective ways
● Lack of valid, reliable, and cost-effective 
ways to measure the impact of an 
intervention on medication adherence 
prevents scale-up of interventions to 
wider clinical practice
10
Target Adherence Interventions to Non-adherent Patients
Conn VS, Ruppar TM, Chase JA, et al. Curr Hypertens Rep. 2015 Dec;17(12):94.
Chase JA, Bogener JL, Ruppar TM,et al. J Cardiovasc Nurs. 2016 Jul-Aug;31(4):357-66. 
Ruppar TM, Delgado JM, Temple J. Eur J Cardiovasc Nurs. 2015 Oct;14(5):395-404.
Adherence intervention studies often 
include a mix of adherent and 
non-adherent patients
For patients with good adherence, 
little or no room to improve
● Limits the effect when measuring outcomes
● Allocates intervention resources poorly 
11
Unintentional vs. Intentional Nonadherence
Most interventions are not designed to assess the 
reasons for nonadherence
Unintentional nonadherence will require a different 
approach than intentional nonadherence
12
Intervention Effects Will Vary Based on Intervention Type
Education and cognitive-
focused interventions tend not 
to change behavior
Need more innovative social 
support interventions
Need better understanding of 
variation in adherence by 
diseases and type of patients
13
Intervention Effects Will Vary Based on Intervention Type
Adapted from: McLeroy KR, Bibeau D, Steckler A, Glanz K. An ecological perspective on health promotion programs. Health Educ Q. 1988;15(4):351-377
Multilevel 
interventions 
are needed 
Focus beyond 
providers
Barriers exist 
at patient, 
provider, and 
systems levels
Cognitive
•Knowledge
•Attitudes 
•Beliefs
•Norms
Behavioral
•Skills, abilities
•Reminders, cues 
•Contractual 
obligations
Motivation/Intention
•Motivation to change
•Intent to change 
•Reward/Benefit
(level-specific)
Environment/Policy
•National/state/local policies
•Institutional policies 
•Home/Work environment
•Resources
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Overcoming Unintentional Nonadherence
For patients with unintentional 
nonadherence, packaging interventions 
are cost-effective first steps
● Pillboxes 
● Blister packs
Integrating medication taking into existing 
habits and routines can be helpful
● Uses behavior prompt to remember medication
● Can be external reminder, phone alarm or 
medication log
Blister Pack
Pill Box
15
Larger Intervention Doses Tend to Be More Effective
Intervention delivery method matters
● Face-to-face are more effective, but 
more expensive
● Trials of face-to-face with mobile health 
follow-up may be more effective than 
just making mobile health tools available
Intervention dose makes a difference
● Measured as either number of times 
or length of time meeting with patient
How to sustain improved adherence beyond the intervention?
16
Challenges
Need interventions that 
incorporate health disparities
● Same disparities seen in disease are 
seen in adherence
Further distinguish between 
reasons for nonadherence
● Unintentional vs. intentional
● Social determinants of health
One year of blister packs for one patient
17
Next Steps
Nieuwlaat R, Wilczynski N, Navarro T, et al. Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011.
Need better ways to measure adherence, 
especially for clinical settings
● Integration of pharmacy data and 
patient-reported data
● Communication between electronic monitoring and 
electronic health records
Move from interventions to long-term 
solutions that support patients
18
Multifaceted Interventions Improve Adherence
P. Michael Ho, MD, PhD
Staff Cardiologist, VA Eastern Colorado Health Care System
Professor of Medicine, University of Colorado Anschutz Medical Campus
19
Patient Case: Mr. A
Dec 2010: Presents with initial heart attack; stent placed and 
started on antiplatelet medication
May 2011: Second heart attack; 
different stent type placed
Nov 2011: Third heart attack; 
switched to different 
antiplatelet medication
June 2012: Fourth heart attack
Angiograms from May 2011
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Discharge 1-month 6-month 12-month
Medication Discontinuation Occurs Earlier Than Expected
Ho PM, Spertus JA, Masoudi FA, et al. Arch Intern Med. 2006 Sep 25;166(17):1842-7.
Beta-Blocker Statin All 3 medsAspirin
Drug Type
Rates of Medication Use for the Entire Cohort, 
By Drug Type and All 3 Medications 
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1 in 7 patients with heart attack 
who receive a stent are no 
longer taking clopidogrel
by 30 days
1 in 6 patients who receive 
a stent do not fill 
clopidogrel prescription
Prematurely Stopping Therapy Is Associated with 
Subsequent Mortality  
The origin is at the time of the patient’s heart attack, but the lines begin at the 1-month assessment point. 
Spertus JA, Kettelkamp R, Vance C, et al. Circulation. 2006 Jun 20;113(24):2803-9.
Ho PM, Tsai TT, Maddox TM, et al. Circ Cardiovasc Qual Outcomes. 2010 May;3(3):261-6. 
Kaplan-Meier Mortality Curves 1 to 12 months after MI, 
By Thienopyridine Therapy at 1 Month after MI 
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Eliminating Co-pays and Costs Can Improve Adherence 
But Still There is Room for Improvement
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ACEi: Angiotensin-converting-enzyme inhibitors
ARB: Angiotensin-receptor blockers
Choudhry NK, Avorn J, Glynn RJ, et al. N Engl J Med. 2011 Dec 1;365(22):2088-97.
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Intentional and Unintentional Reasons for Nonadherence
Medication Adherence in America: A National Report 2013. ncpanet.org/pdf/reportcard/AdherenceReportCard_Abridged.pdf
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Hospitalization 
for acute 
myocardial 
infarction or  
unstable angina
Hospital discharge: Patients received 
standard discharge instructions
Outpatient
pharmacist 
telephone 
contact
Month 1
Months 2–12: Monthly medication refill calls
Usual Care
Intervention
Medication 
reconciliation
with pharmacist
7-10 
days
12-month
Follow-up visit
Multifaceted Intervention to Improve Cardiac Medication 
Adherence and Secondary Prevention Measures (MEDICATION) Study
Ho PM, Lambert-Kerzner A, Carey EP, et al. JAMA Intern Med. 2014 Feb 1;174(2):186-93.
Automated phone 
calls and 
pharmacist contact 
as needed
Months 2–6: 
Monthly education 
and medication 
reminder calls
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Higher Adherence in Patients Receiving Multifaceted Intervention
Proportion of Patients Adherent to Medications  
PDC: Proportion of days covered. The number of days the member is covered by at least one medication prescription of appropriate intensity, divided 
by the number of days in the treatment period.  * p<0.05
Ho PM, Lambert-Kerzner A, Carey EP, et al. JAMA Intern Med. 2014 Feb 1;174(2):186-93.
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Modest Intervention Costs and Similar Total Costs at 12 Months
Ho PM, Lambert-Kerzner A, Carey EP, et al. JAMA Intern Med. 2014 Feb 1;174(2):186-93. 
Costs Usual Care Intervention P-value
Intervention $0 $360
Cardiac medications $663 $722 0.70
Total medications $2,724 $2,887 0.43
Total outpatient $11,691 $13,086 0.53
Total inpatient $14,287 $11,294 0.68
Total 
(intervention, medication, 
outpatient, and inpatient)
$19,989 $19,901 0.56
27
Positive Relationships With Providers 
Bidirectional Communication Key to Improving Adherence 
Mutually respectful collaboration with their providers
Importance of hearing the patients’ perspectives and concerns
Patients became comfortable disagreeing with the providers’ 
recommendations or asking clarifying questions 
Patients became active participants in the development of their 
treatment plan, which they believed was essential for high-quality care
Lambert-Kerzner A, Havranek EP, Plomondon ME, et al. Patient Prefer Adherence. 2015 Jul 24;9:1053-9.
28
Frequent Interactions With Study Pharmacists and 
Medication Refill Reminder Calls Improved Adherence
Two-thirds of the intervention arm had positive experiences, 
specifically with the study pharmacists, 
who were seen as supportive providers and caring people
“… it made me think that it musta’ been more important 
than I thought it was … to have these people contact me 
on a regular basis to make sure I was takin’ it.”
Lambert-Kerzner A, Havranek EP, Plomondon ME, et al. Patient Prefer Adherence. 2015 Jul 24;9:1053-9.
29
Additional Factors That Improved Adherence
Important in improving 
their lives
● Social support from family 
and friends
● Medication-taking routines
● Specific adherence tools 
Lambert-Kerzner A, Havranek EP, Plomondon ME, et al. Patient Prefer Adherence. 2015 Jul 24;9:1053-9.
30
Multimodal and Team-based Interventions 
Can Improve Adherence
Medication non-adherence is common
Reasons for non-adherence are multifactorial and change over time
Multimodal and team-based interventions that address different 
reasons for nonadherence are more likely to be successful
Mutually respectful collaborations encourage patients to become 
active participants in the development of their treatment plan, and led 
to better adherence
Interventions leveraging data and technology are needed to improve 
adherence while remaining cost-effective
31
Promoting Medication Adherence Through High-Tech and High-Touch
Larry Garber, MD
Medical Director, Informatics
Associate Medical Director for Research
Reliant Medical Group
32
Over 500 provider multi-specialty group practice in 
central Massachusetts 
● Not affiliated with any hospitals and not-for-profit 
● Over 50% Pay-for-Performance
20,000 hypertensive patients
● In 2011, only 68% of hypertensive patients were under control, but
nationally 90th percentile for control was over 72% of patients
● In 2012, Reliant initiated a hypertension control program 
● Included focus on medication adherence
33
How to Promote Medication Adherence
Ensure that patient understands 
the benefits
Choose lower cost medications and 
ones that are easier to take 
Minimize medication side effects
Show the effectiveness of the 
medications in lowering blood pressure 
Monitor medication adherence
34
Empower the Patient Through Education
EHR: Electronic health record 
Educate on the harms of uncontrolled hypertension
and the benefits of controlling hypertension
Make education materials widely available
● On Reliant’s trusted website
● Automatically print on the After-Visit Summary 
if diagnosis of hypertension
● Available within EHR and adjustable 
computer monitors designed to 
be visible to the patient
Demonstrate that alternatives have failed
● Graph of blood pressure trends within EHR 
prior to medications
35
Empower the Provider to 
Choose Appropriate and Lower Cost Medications
EHR: Electronic health record 
Use step-therapy protocols
● Developed by multidisciplinary team
● Standardized across organization
Control access to 
pharmaceutical marketing
Show patient’s payer-specific 
formulary in EHR
Generic substitution mandated 
in state
Hypertension Medication Protocol Pathways
Patient Characteristic Path to Follow
Black (unless presents with 
fluid overload)
Path #1
Clinical fluid overload at presentation Path #2
>60 years old Path #3
<60 or Diabetes or Renal disease 
(if fluid overload - go to pathway #5)
Path #4
Diabetic/Renal disease with fluid
overload initially
Path #5
36
Empower the Provider to
Minimize Medication Complexity and Expense
EHR: Electronic health record 
Choose once-a-day and combos 
for convenience
Engage in dialogue about costs vs convenience
● Pill-splitting can reduce cost but can be 
inconvenient for patient to split them
Provide assistance in paying for medications
● RxAssist.org website hyperlink within EHR 
● Consult Reliant’s social workers
37
Minimize Medication Side Effects
ACE: Angiotensin Converting Enzyme
Be creative in addressing concerns 
● Concern about swollen feet  use a diuretic
● Concern about medication causing too high or too low potassium level 
combine ACE-Inhibitor + diuretic to normalize potassium
Monitor side effects
● At visits
● At renewals, using standard template
● After hospital discharge – automated warnings
Consult Reliant’s pharmacists
● Complex medication regimens or problems
● After hospital discharge
38
Show Effectiveness of Medications in Lowering Blood Pressure
BP: Blood pressure
EHR: Electronic health records
Empower patient to record BPs at home 
● Provide booklets to record readings
● For financial hardship, give out free monitors
Free BP clinics at Reliant
Automatically upload BP readings into EHR 
via Microsoft HealthVault®
Show graphs of trends in EHR
Patients can view graphs of trends at home
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Monitor Medication Adherence
Surescripts® medication fill history
Payer medication claims
● Loaded into EHR nightly
● Shows dates and days of supply picked up
Review during visits
● Knowing that clinician can be watching 
adherence is at least as important as 
seeing the results
Automate compliance monitoring? 
EHR: Electronic health records
Display of Pharmacy Refills
40
Hypertension Interventions’ Outcome
2012 2013 2014 20152011
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Lessons Learned
BP: Blood pressure
Educate and empower patients
Make medication adherence and 
BP monitoring easy for the patient
Offload work from physician to 
other team members
Patients knowing that you can 
monitor medication adherence may 
be more important than actually 
monitoring medication adherence
42
Next Steps
BP: Blood pressure
Expand home BP monitoring options to include smartphone 
authentication and aggregation
Consider financial incentives to patients and care team for 
hypertension control
43
Looking to the Future: Personalize Health Risk
BMI: Body mass index
Patient-friendly Health Risk Assessment Tools
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Broadening Public Health Approaches to 
Medication Adherence for HIV
CAPT Paul J Weidle, PharmD, MPH
Team Lead, Health Services Research for Prevention with HIV Positive Persons
Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
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Medication Adherence Is Important for Treatment 
and Prevention in HIV Disease
aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
cdc.gov/hiv/pdf/policies/cdc-hiv-prevention-bluebook.pdf
Cohen MS, Chen YQ, McCauley M, et al. N Engl J Med. 2016 Sep 1;375(9):830-9. 
Antiretroviral treatment reduces the amount of 
HIV virus circulating in the blood
● Improve immune function and health of people with HIV 
● Reduce transmission by 90% or more 
● Since 2012, recommended for all persons living with HIV
in the United States
To maximize health and prevent HIV transmission, 
medication adherence must achieve viral suppression
● HIV viral load is a direct proxy for adherence to treatment 
and is typically tested at least twice per year
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HIV Treatment That Leads to Viral Suppression 
Reduces HIV Transmission
3 out of every 5 new HIV 
infections can be attributed 
to people who have been 
diagnosed with HIV but are 
not in care
Few HIV transmissions occur 
when care is optimized and 
viral suppression is achieved
ART: Antiretroviral treatment
Skarbinski J, Rosenberg E, Paz-Bailey G, et al. JAMA Intern Med. 2015 Apr;175(4):588-96. 
Estimated Number of HIV Transmissions 
Along the HIV Care Continuum, U.S., 2009
~45,000 HIV transmissions in 2009
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National HIV/AIDS Strategy Goals by 2020
aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf
Reduce new HIV infections
Increase access to HIV care 
and improve health outcomes 
for people living with HIV
Reduce HIV-related 
health disparities and 
health inequities
48
National HIV/AIDS Strategy Goals by 2020
for the Newly Diagnosed
aids.gov/federal-resources/national-hiv-aids-strategy/nhas-indicators-supplement-dec-2016.pdf
Goal: At least 85 percent of 
newly diagnosed persons are 
linked to HIV medical care within 
one month of their HIV diagnosis
● In 2014, 74.5% of persons newly 
diagnosed with HIV were linked to 
HIV medical care within one month 
of diagnosis
49
National HIV/AIDS Strategy Goals by 2020
for Retention in Care and Viral Suppression 
Goal: At least 90 percent of persons with diagnosed HIV infection are 
retained in HIV medical care
● In 2013, more than half (56.5%) of persons with diagnosed HIV infection were 
retained in HIV medical care
Goal: At least 80 percent of persons with diagnosed HIV infection are 
virally suppressed
● In 2013, more than half (54.7%) of persons with diagnosed HIV infection were 
virally suppressed
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National HIV Surveillance System
cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-4.pdf
Health departments collect 
laboratory data to monitor 
progress towards goals 
● HIV diagnostic tests
● CD4+ cell counts 
● HIV viral load 
● HIV resistance tests
As of December 2015, in 33 
jurisdictions, at least 95% of 
tests are reported
Jurisdictions Reporting, December 2015
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Public Health Role to Improve Health of Persons Living with HIV 
and to Prevent Transmission of HIV
effectiveinterventions.cdc.gov/en/HighImpactPrevention/PublicHealthStrategies/DatatoCare.aspx
The Data to Care Strategy aims to use HIV surveillance data to identify 
persons diagnosed with HIV who are not receiving HIV care and link 
them to care
● Persons who either never linked to care after diagnosis
● Persons who did not continue to receive care
52
Three Models to Connect Individuals to HIV Care
effectiveinterventions.cdc.gov/en/HighImpactPrevention/PublicHealthStrategies/DatatoCare.aspx
Health Department Model
● Health department-initiated linkage and re-engagement outreach
Healthcare Provider Model
● Healthcare provider-initiated linkage and re-engagement outreach
Combination Health Department and Healthcare Provider Model
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Using HIV Surveillance Data to Support the HIV Care Continuum
effectiveinterventions.cdc.gov/en/HighImpactPrevention/PublicHealthStrategies/DatatoCare.aspx
Use health department HIV surveillance database to identify 
individuals who are probably not in HIV medical care currently
● Vital records status “Alive” 
● Currently residing in jurisdiction
● HIV diagnosis at or before the end of a specified time period
No CD4+ cell count or viral load result during a specified time period 
● Time interval can be as short as 6 months
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Finding and Connecting People to HIV Care
effectiveinterventions.cdc.gov/en/HighImpactPrevention/PublicHealthStrategies/DatatoCare.aspx
Investigate out-of-care list
● Fill in important information that might be missing from an individual’s record 
(e.g., current telephone number or address)
● Check with the last known care provider
● Match out-of-care list to databases internal and external to health department
Share key data with field services staff and care providers 
Reach out to individuals on the out-of-care list 
● Identify barriers and link or re-engage into care
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Evidence That the Data to Care Strategy Can Improve 
Re-linkage to Care  
Bove JM, Golden MR, Dhanireddy S, et al. J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):262-8.
Combined healthcare provider and health department model 
Largest HIV clinic in Washington State 
● Criteria: No visit > 12 months
Outreach
● Clinic-based linkage specialist 
 Phone call x 3, email x 1, call emergency contact
● Department of health relinkage team 
Shorter time to re-link and 
more re-linked to care
● Compared to historical controls
56
Data to Care Strategy
Cooperative Re-engagement in Care Controlled Trial (CoRECT)
Establish a data-sharing partnership between health departments and 
HIV care providers to identify HIV-infected persons who are out of care
● Necessary to share and protect data
Implement a health department field services intervention and identify 
barriers to care
● Link to an HIV clinic within 90 days
● Remain in HIV medical care at least 12 months
● Achieve HIV viral load suppression within 12 months
● Achieve durable HIV viral load suppression for 12–18 months
● Sites in Connecticut, Philadelphia, Massachusetts
clinicaltrials.gov/ct2/show/NCT02693145?term=corect&rank=1
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Data to Care Strategy
Partnerships for Care (P4C) 
HRSA: Health Resources and Services Administration EHR: Electronic health records 
cdc.gov/hiv/research/demonstration/p4c/index.html 
Multi-agency federal partnership
● Co-led by CDC and HRSA’s Bureau of Primary Health Care
Use HIV surveillance data and health-center EHR to improve HIV 
health outcomes for persons living with HIV who are not in care
● Sites in Florida, Maryland, Massachusetts, New York State
58
Data to Care Strategy
Targeted Highly Effective Intervention to Reverse the HIV Epidemic
cdc.gov/hiv/funding/announcements/ps15-1509/index.html
Implements comprehensive HIV prevention and care services for men 
who have sex with men
● Includes a Data to Care strategy to re-engage them in care
● Sites in Alabama, Baltimore, District of Columbia, Louisiana, New York City, 
Philadelphia, Virginia
59
Data to Care Strategy
Project PrIDE
cdc.gov/hiv/research/demonstration/projectpride.html    
Supports men who have sex with men and transgender persons not in 
HIV care and re-engage them in care
Implementing Data to Care demonstration projects
● Sites in Baltimore, Chicago, Houston, Louisiana, San Francisco
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By Re-engaging Persons Living with HIV In Care, Public Health Can 
Improve Their Health and Prevent HIV Transmission
cdc.gov/actagainstaids/campaigns/hivtreatmentworks
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Together We Can Overcome Barriers to 
Medication Adherence and Improve Lives
Adhering to medications improves the lives 
of people with chronic diseases
Nonadherence is common and multifactorial
● Up to half of persons on medications are non-adherent
Many ways to reduce barriers exist, 
but more ways are needed
● Along with better understanding of what works, and with whom
Working together, we can reduce these barriers and improve 
adherence and peoples lives
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